Safety & Risk ManagementSet & Setting

Prevalence and associations of challenging, difficult or distressing experiences using classic psychedelics

This survey study (n=2822) examined the prevalence and associations of challenging, difficult, or distressing experiences using classic psychedelics in a subsample of respondents (n=613) who reported lifetime classic psychedelic use. Of those, 59% indicated no challenging experiences, 9% indicated having a difficult experience lasting more than one day, and 2.6% reported seeking medical/psychiatric/psychological assistance.

Authors

  • Otto Simonsson
  • Peter Hendricks
  • Wojciech Osika

Published

Journal of Affective Disorders
individual Study

Abstract

Previous studies have investigated challenging, difficult, or distressing experiences using classic psychedelics, but little is known about the prevalence and associations of such experiences. Using nationally representative data of the US adult population (N = 2822), this study examined the prevalence and associations of challenging experiences using classic psychedelics, in a subsample of respondents who reported lifetime classic psychedelic use (n = 613). Of the 613 respondents who reported lifetime classic psychedelic use, the majority of them (59.1 %) had never had a challenging, difficult, or distressing experience using a classic psychedelic, but 8.9 % of respondents reported functional impairment that lasted longer than one day. Notably, 2.6 % reported seeking medical, psychiatric, or psychological assistance in the days or weeks following their most challenging, difficult, or distressing experience. In covariate-adjusted regression models, co-use of lithium, co-use of other mood stabilizers, and six set and setting variables (no preparation, disagreeable physical environment, negative mindset, no psychological support, dose was too large, major life event prior to experience) were associated with the degree of difficulty during respondents' most challenging classic psychedelic experience; and co-use of lithium, co-use of other mood stabilizers, and three set and setting variables (negative mindset, no psychological support, major life event prior to experience) were associated with overall risk of harm. In summary, this study provides insight into the prevalence and associations of challenging, difficult, or distressing classic psychedelic experiences. The findings broadly correspond with findings from previous studies and can inform harm reduction efforts and future experimental research designs.

Available with Blossom Pro

Research Summary of 'Prevalence and associations of challenging, difficult or distressing experiences using classic psychedelics'

Introduction

Classic serotonergic (5-HT2A agonist) psychedelics such as psilocybin are increasingly studied for therapeutic potential and generally show a favourable safety profile in controlled trials when combined with psychological support. However, most clinical work has used carefully screened participants in highly structured settings, leaving uncertainty about risks arising from use in broader, naturalistic contexts. Existing guidelines therefore emphasise screening (for example, excluding people taking certain medications such as lithium) and attentiveness to set (psychological state) and setting (physical and social environment) as ways to reduce harm, but population-level data on the prevalence and correlates of challenging, difficult, or distressing psychedelic experiences are limited. Simonsson and colleagues set out to address that gap by conducting exploratory analyses of challenging experiences among lifetime users of classic psychedelics within a nationally representative sample of US adults (with respect to sex, age and ethnicity). The study aimed to estimate prevalence of such experiences, describe their phenomenology and immediate consequences, and examine associations between medication co-use, set and setting variables, and both the intensity of challenging experiences and subsequent risk of harm.

Expert Research Summaries

Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.

Full Text PDF

Full Paper PDF

Pro members can view the original manuscript directly in the browser.

Study Details

References (14)

Papers cited by this study that are also in Blossom

Trial of Psilocybin versus Escitalopram for Depression

Carhart-Harris, R. L., Giribaldi, B., Watts, R. et al. · New England Journal of Medicine (2021)

927 cited
Human hallucinogen research: guidelines for safety

Johnson, M. W., Richards, W. A., Griffiths, R. R. · Journal of Psychopharmacology (2008)

The Challenging Experience Questionnaire: Characterization of challenging experiences with psilocybin mushrooms

Barrett, F. S., Bradstreet, M. P., Leoutsakos, J. M. S. et al. · Journal of Psychopharmacology (2016)

Lysergic acid diethylamide: side effects and complications

Cohen, S. · Journal of Nervous and Mental Disease (1980)

Adverse Reactions to Psychedelic Drugs - A Review of the Literature

Strassman, R. J. · Journal of Nervous and Mental Disease (1984)

273 cited
Making “bad trips” good: How users of psychedelics narratively transform challenging trips into valuable experiences

Gashi, L., Sandberg, S., Pedersen, W. · International Journal of Drug Policy (2021)

Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences

Carbonaro, T. M., Bradstreet, M. P., Barrett, F. S. et al. · Journal of Psychopharmacology (2016)

Neuroticism is associated with challenging experiences with psilocybin mushrooms

Barrett, F. S., Johnson, M. W., Griffiths, R. R. · Personality and Individual Differences (2017)

78 cited
Predicting responses to psychedelics: a prospective study

Haijen, E. C. H. M., Kaelen, M., Roseman, L. et al. · Frontiers in Pharmacology (2018)

339 cited
Show all 14 references
Associations between lifetime classic psychedelic use and markers of physical health

Simonsson, O., Sexton, J. D., Hendricks, P. S. · Journal of Psychopharmacology (2021)

65 cited
Psychedelics, meditation, and self-consciousness

Milliere, R., Carhart-Harris, R. L., Roseman, L. et al. · Frontiers in Psychology (2018)

Combining Psychedelic and Mindfulness Interventions: Synergies to Inform Clinical Practice

Payne, J. E., Chambers, R., Liknaitzky, P. · ACS Pharmacology and Translational Science (2021)

55 cited

Cited By (20)

Papers in Blossom that reference this study

Post-traumatic stress disorder symptoms following psychedelic use: a naturalistic survey study

Evens, R., Uyar, A., Gosslau, E. et al. · Psychological Medicine (2026)

Do Psychedelics Mimic Psychosis? Perspectives on Similarities and Differences from Individuals with Lived Experience of Psychosis and Psychedelics

Dourron, H. M., Bradley, M. K., Copes, H. et al. · International Journal of Mental Health and Addiction (2026)

Naturalistic psychedelic use and changes in depressive symptoms

Simonsson, O., Hendricks, P. S., Swords, C. M. et al. · Journal of Affective Disorders (2025)

On Minimizing Risk and Harm in the Use of Psychedelic

Evans, J., Aixalà, M., Anderson, B. T. et al. · Psychiatric Research & Clinical Practice (2025)

Shame, guilt and psychedelic experience: Results from a prospective, longitudinal survey of real-world psilocybin use

Mathai, D. S., Roberts, D. E., Nayak, S. M. et al. · Journal of Psychedelic Drugs (2025)

Naturalistic psychedelic therapy: The role of relaxation and subjective drug effects in antidepressant response

Calder, A. E., Rausch, B., Liechti, M. E. et al. · Journal of Psychopharmacology (2024)

Show all 20 papers
Unique Psychological Mechanisms Underlying Psilocybin Therapy Versus Escitalopram Treatment in the Treatment of Major Depressive Disorder

Weiss, B., Leor Roseman, •., Giribaldi, B. et al. · International Journal of Mental Health and Addiction (2024)

Set and setting predict psychopathology, wellbeing and meaningfulness of psychedelic experiences: a correlational study

Borkel, L. F., Rojas-Hernández, J., Henríquez-Hernández, L. A. et al. · Expert Review of Clinical Pharmacology (2023)

Extended difficulties following the use of psychedelic drugs: A mixed methods study

Evans, J., Robinson, O., Ketzitzidou-Argyri, E. et al. · PLOS ONE (2023)

123 cited
Longitudinal associations between psychedelic use and meditation practices in the United States and the United Kingdom

Simonsson, O., Osika, W., Stenfors, C. U. D. et al. · Psychological Medicine (2023)

Nature-themed video intervention may improve cardiovascular safety of psilocybin-assisted therapy for alcohol use disorder

Heinzerling, K. G., Sergi, K., Linton, M. et al. · Frontiers in Psychiatry (2023)

Co-use of MDMA with psilocybin/LSD may buffer against challenging experiences and enhance positive experiences

Zeifman, R. J., Kettner, H., Pagni, B. A. et al. · Scientific Reports (2023)

22 cited
Therapeutic mechanisms of psychedelics and entactogens

Heifets, B. D., Olson, D. E. · Neuropsychopharmacology (2023)

Your Personal Research Library

Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.